Clinical Trials Logo

Filter by:
NCT ID: NCT00464880 Completed - Diabetes Type 2 Clinical Trials

Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Start date: September 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.

NCT ID: NCT00464776 Completed - Clinical trials for Diabetes Mellitus, Type 2

Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy

NCT ID: NCT00464165 Completed - Smoking Cessation Clinical Trials

Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation

STRATUS-EU
Start date: November 2002
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period and to observe the percentage of abstinent subjects during a 40-week follow-up post treatment.

NCT ID: NCT00464035 Completed - Obesity Clinical Trials

The Effect of Calcium on Postprandial Lipid Profile and Appetite

Start date: February 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of calcium on postprandial lipid profile and appetite.

NCT ID: NCT00463216 Completed - Back Pain Clinical Trials

A Coordinated Return to Work Program

Start date: April 2004
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the possibility that a diagnostic evaluation by a multidisciplinary team reduces the length of sick leave.

NCT ID: NCT00463203 Completed - Glioma Clinical Trials

Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Start date: March 2007
Phase: Phase 2
Study type: Interventional

Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas. Recent data form a small study of 32 patients from Duke University have achieved a response rate of 62% in patients with malignant gliomas. Most included patients had glioblastomas, but this regimen may also have activity in more rare primary malignant brain tumors. The investigators therefore plan to include other primary malignant brain tumors in this study, and the clinical activity will be correlated with biomarkers and PET results of metabolic activity and blood flow. This may result in information that can be used to individualize therapy in the future.

NCT ID: NCT00463073 Completed - Malignant Gliomas Clinical Trials

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Start date: August 2006
Phase: Phase 2
Study type: Interventional

Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas. In addition, 40-50 % of GBM have EGFR amplification/mutation making the EGFR an additional target. By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone. In addition, recurrent gliomas have an extremely poor prognosis, so innovative therapies are needed.

NCT ID: NCT00462241 Completed - Clinical trials for Non-cardiac Chest Pain

Treatment Study Comparing Manual Treatment or Advice in Acute, Musculoskeletal Chest Pain

CARPA
Start date: August 2006
Phase: N/A
Study type: Interventional

Acute chest pain is a common cause of hospital admission. Active approaches are directed towards diagnosis and treatment of potentially life threatening conditions, especially acute coronary syndrome and coronary artery disease. However, a considerable number of patients may have chest pain caused by biomechanical dysfunction of muscles and joints of the chest wall or the cervical and thoracic spine (20%). The diagnostic approaches and treatment options for this group of patients are scarce and there is a lack of formal clinical studies and validated outcome measures addressing the effect of manual treatment approaches. Objective: This single blind randomized clinical trial investigates whether chiropractic treatment can reduce pain and improve function in a population of patients with acute, musculoskeletal chest pain when compared to advice directed towards promoting self-management. Methods: Among patients admitted to a chest pain clinic in a university hospital under suspicion of acute coronary syndrome, 120 patients with an episode of acute chest pain of musculoskeletal origin are included in the study. All patients have completed the chest pain clinic diagnostic procedures, and acute coronary syndrome and other obvious reasons for chest pain have been excluded. After completion of the study evaluation program, the patients are randomized into one of two groups: A) advice promoting self-management and individual instructions focusing on posture and muscle stretch; B) a course of chiropractic therapy of up to ten treatment sessions focusing on high velocity, low amplitude manipulation of the cervical and thoracic spine together with a choice of mobilisation and soft tissue techniques. In order to establish suitable outcome measures, two pilot studies were conducted. Outcome measures are pain, function, overall health, and patient-rated treatment effect measured at 4, 12, and 52 weeks following treatment.

NCT ID: NCT00461136 Completed - Diabetes Type 2 Clinical Trials

Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

Start date: August 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.

NCT ID: NCT00460512 Completed - Schizophrenia Clinical Trials

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

PERFlexS
Start date: April 25, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) previously unsuccessfully treated with an oral antipsychotic medication.